GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Total Stockholders Equity

CytoDyn (CytoDyn) Total Stockholders Equity : $-119.38 Mil (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Total Stockholders Equity?

CytoDyn's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-119.38 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CytoDyn's Book Value per Share for the quarter that ended in Feb. 2024 was $-0.12. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CytoDyn's Debt-to-Equity for the quarter that ended in Feb. 2024 was -0.26.

CytoDyn Total Stockholders Equity Historical Data

The historical data trend for CytoDyn's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Total Stockholders Equity Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.91 -2.48 -21.02 -94.40 -109.50

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -107.01 -109.50 -116.89 -114.38 -119.38

CytoDyn  (OTCPK:CYDY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CytoDyn's Book Value per Share for the quarter that ended in Feb. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-119.382-0)/989.925
=-0.12

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CytoDyn's Debt-to-Equity for the quarter that ended in Feb. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(30.311 + 0.176) / -119.382
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of CytoDyn's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Total Stockholders Equity
Comparable Companies
VOR TELO BSEM ACRV ACHV BCAB GNLX ARMP IMAB SGMT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
296:Germany
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
Website
https://www.cytodyn.com
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660